

10534358

534358

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



PCT

(43) International Publication Date  
21 May 2004 (21.05.2004)

(10) International Publication Number  
WO 2004/041773 A1

(51) International Patent Classification<sup>7</sup>: C07C 211/42

CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:  
PCT/IB2003/004998

(84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, BE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date:  
3 November 2003 (03.11.2003)

**Declaration under Rule 4.17:**

— *of inventorship (Rule 4.17(iv)) for US only*

(25) Filing Language:  
English

**Published:**

(26) Publication Language:  
English

— *with international search report*  
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(30) Priority Data:  
628/CAL/2002 7 November 2002 (07.11.2002) IN

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(71) Applicant and  
(72) Inventor: NADKARNI, Sunil, Sadanand [IN/IN]; Torrent Pharmaceuticals Ltd., Torrent Research Centre, Dist: Gandhinagar, Gujarat 382 428 (IN).

(74) Agents: AHUJA, Sudhir, D. et al.; D.P. Ahuja & Co., 53, Syed Amir Ali Avenue,, Calcutta 700 019, West Bengal (IN).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR,

WO 2004/041773 A1

(54) Title: PROCESS FOR PREPARATION OF POLYMORPHIC FORM OF SERTRALINE HYDROCHLORIDE

(57) Abstract: The invention discloses a process for preparation of sertraline salts particularly sertraline hydrochloride Form V by dissolving or suspending sertraline mandelate in a solvent, reducing the pH of the solution or the suspension and isolating salt of sertraline. The invention also provides for a pharmaceutical composition comprising said sertraline salt as active ingredient.

# PROCESS FOR PREPARATION OF POLYMORPHIC FORM OF SERTRALINE HYDROCHLORIDE

## BACKGROUND OF THE INVENTION


5

### FIELD OF THE INVENTION

This invention relates to a process for the preparation of polymorphic Form V of (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthaleneamine hydrochloride i.e. sertraline hydrochloride. Sertraline hydrochloride is an agent for treatment for depression, obsessive-compulsive disorder and panic disorder (WO 00/32551).

### DESCRIPTION OF THE PRIOR ART

The need for the drugs, which lack the obtrusive and limiting side effects of the tricyclic antidepressants had prompted the search for agents with greatly enhanced selectivity for specific mechanisms of actions believed to be essential for antidepressant efficacy. Researches targeted for selective competitive inhibitors of synaptosomal serotonin re-uptake, which led to series of 1-methylamine-4-aryltetralins, of which the most promising was the 4-(3,4-dichlorophenyl) analogue. Testing of all possible stereoisomers revealed that the required high selectivity for serotonin resides in the cis-1S,4S isomer i.e. (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthaleneamine hydrochloride (I) commonly known as sertraline hydrochloride.



In the literature various polymorphic forms of sertraline hydrochloride have been described. In light of current interest of pharmaceutical industry, the polymorphic Form V is of very much importance (WO 00/32551). Hence, a need was felt to 5 produce the polymorphic Form V of sertraline hydrochloride in bulk by a process which is both efficient and cost-effective.

The "sublimation – condensation method" for preparation of Form V is disclosed in US Patent No. 5,248,699. However, the said "sublimation – condensation method" is 10 not practical on a commercial scale, considering the demand of sertraline hydrochloride Form - V. This is especially because "sublimation – condensation method" requires special assembly, wherein simultaneously high vacuum and temperature is required to be applied to sublime the starting material, whereas to collect the sublimation product, it invites the special apparatus and skills. Further 15 more, the complexity of the issue is compounded as per the disclosure in WO 0032551, because the "sublimation – condensation method" is not found to be reproducible.

WO 0032551 and WO 0172684 mainly uses sertraline hydrochloride (Scheme - 1) or sertraline base (Scheme - 2) for making sertraline hydrochloride Form V.

**Scheme - 1**

5

Sertraline mandelate → Sertraline Base → Sertraline. HCl → Sertraline HCl Form V

**Scheme - 2**

10     Sertraline mendelate → Sertraline Base → Sertraline HCl Form V

Further, WO 0132601 discloses processes for making sertraline hydrochloride Form V from using sertraline base. The preparation of sertraline hydrochloride Form V  
15 using the teachings of WO 0132601 Scheme - 3 or Scheme - 4. is as given below:

**Scheme - 3**

Sertraline mandelate → Sertraline Base → Sertraline. HCl (Form - CSC 2) →  
Sertraline HCl Form V.

20

**Scheme - 4**

Sertraline mandelate → Sertraline Base → Sertraline. HCl → Sertraline HCl Alcohol  
Solvate → Sertraline HCl Form V.

25     As per procedures disclosed in US 5248699, US 4536518, WO 032551, the sertraline base is prepared using sertraline mandelate that involves a number of steps implying increase in utilities, manpower, time required to complete the production cycle. Thus, the said processes are commercially expensive.


Thus a need was felt for production of the polymorphic Form V of sertraline hydrochloride by a simple, efficient and cost effective process.

5

### OBJECTS OF THE INVENTION

The first object of the present invention is to provide an efficient and cost effective process for the preparation of sertraline salts.

- 10 The second object of the present invention is to provide an efficient and cost effective process for the preparation of the polymorphic Form V of sertraline hydrochloride.



- 15 The third object of the present invention is to produce sertraline hydrochloride Form V having characteristic X-ray diffraction pattern data (XRPD).

The fourth object of the invention is to produce for sertraline hydrochloride Form V having characteristics ICR spectrum.

The fifth object of the invention is to provide a pharmaceutical composition with sertraline hydrochloride Form V as the active ingredient.

### SUMMARY OF THE INVENTION

5

The present invention provides for a process for the production of sertraline salt, comprising the steps of :

- a) dissolving or suspending sertraline mandelate in a solvent ;
- b) reducing the pH of the solution or the suspension and
- 10 c) isolating salt of sertraline.

The present invention also provides for a process for the production of sertraline hydrochloride Form V comprising the steps of :

- a) dissolving or suspending sertraline mandelate in a solvent ;
- 15 b) reducing the pH of the solution or the suspension and
- c) isolating sertraline hydrochloride Form V.

The present invention further provides for a process for preparation of a pharmaceutical composition of sertraline hydrochloride Form V by using sertraline hydrochloride Form V as active ingredient.

### DETAILED DESCRIPTION OF THE INVENTION

Sertraline hydrochloride of formula (I) exists in different polymorphic forms, viz. Form I to XVI, T1, CSC - 1, CSC - 2 and amorphous Form. Crystallization for polymorphs is normally done by dissolving or melting the compound followed by

gradual or fast cooling of the resultant solution or molten liquid. Different polymorphic forms are identical in solution as evident from their NMR, IR (solution spectra data). On the other hand, solid-state techniques like X-ray or IR (KBr spectra) revealed the difference between polymorphic Forms.

5

The present invention provides new process for making sertraline hydrochloride Form V starting from sertraline mandelate.

According to the instant process, sertraline mandelate need not be converted into 10 sertraline base and subsequently into sertraline hydrochloride unlike the prior art processes. The multiple steps involved in the prior art processes including an intermediate step for conversion of sertraline mandelate into sertraline base or sertraline hydrochloride of different Form (other than Form V) of sertraline hydrochloride is avoided because the present invention provides converting sertraline 15 mandelate to sertraline hydrochloride Form V directly. Thus, the present invention provides the manufacturing process, which reduces number of steps implying decrease in utilities, manpower, time required to complete the production cycle. Thus, the instant invention provides a simple one-step process for production of sertraline hydrochloride Form V in an efficient and cost effective manner.

20

A process according to the instant invention for the production of sertraline salt, is comprising the steps of :

- d) dissolving or suspending sertraline mandelate in a solvent ;
- e) reducing the pH of the solution or the suspension and
- f) isolating salt of sertraline.

The polymorphic Form V of sertraline hydrochloride is prepared according to the instant invention by a process comprising

- d) dissolving or suspending sertraline mandelate in a solvent ;
- e) reducing the pH of the solution or the suspension and
- 5 f) isolating sertraline hydrochloride Form V.

The solvent used for dissolving or suspending sertraline mandelate is selected from the group comprising of protic solvents or mixture thereof.

10 The solvent used for dissolving or suspending sertraline mandelate is selected from the group consisting of alcohol, water and mixtures thereof. The alcohols can be selected from methanol, ethanol, n-propanol, isopropanol, n-butyl alcohol, t-butyl alcohol, isobutyl alcohol and mixtures thereof. The preferable solvent is isopropanol.

15 The dissolving or suspending is achieved by heating and / or stirring. Heating can be done upto 90 °C. Preferably sertraline mandelate is dissolved at 25-80°C and more preferably at 25 - 30°C under stirring.

Reduction of pH can be done by using organic or inorganic acids. The reduction of  
20 pH is preferably done by inorganic acids such as HCl, H<sub>2</sub>SO<sub>4</sub>, HNO<sub>3</sub>.

HCl is taken in the form of gas or dissolved in a solvent. The solvent can be water or organic solvent or mixtures thereof. The organic solvent can be selected from the alcoholic solvent such as methanol, ethanol, n-propanol, isopropyl alcohol, n-butanol  
25 or mixtures thereof.

Preferably, the reduction of pH is done by using aqueous HCl.

After reduction of pH in the range of 1 - 3, preferably 1-2, the reaction mixture can be either clear solution or even can be kept in suspension form. The clear solution can be obtained optionally by heating upto 90 °C.

5

The cooling is effected by allowing the solution to attain room temperature on its own or with mild coolants comprising of cold water, water, alcohols or mixtures thereof.

The alcohol is selected from the group comprising of monohydroxy alcohol, dihydroxy alcohol or mixtures thereof. Further, solid obtained can be isolated to get

10 Form V.

The process according to the instant invention is given in Scheme - 5.

### Scheme - 5

15

Sertraline mendelate → Sertraline HCl Form V

According to a preferred embodiment of the process of the instant invention, sertraline mandelate is treated with isopropyl alcoholic HCl. The pH is adjusted to 1-  
20 2 and water was added followed by heating the reaction mass to get the clear solution, which after cooling gave directly sertraline hydrochloride Form V.

The starting compound sertraline mandelate may be prepared according to the procedures disclosed in EP 30081. The preparation of highly pure sertraline  
25 mandelate is advantageous as it does not demand more time and labour for repeated crystallizations. Sertraline mandelate is prepared according to the instant invention

by a process, wherein purification by repeated crystallization is not required. Also, there is no need to obtain the second crop similar to EP 30081.

A pharmaceutical composition can be obtained by using therapeutically effective 5 amount of sertraline hydrochloride Form V thus obtained with a pharmaceutically acceptable carrier.

#### **BRIEF DESCRIPTION OF THE ACCOMPANYING DRAWINGS :**

10 **Fig. 1 :** This figure indicates X-ray diffraction pattern of the compound obtained according to the present invention.

**Fig. 2 :** This figure indicates IR spectrum of the compound obtained according to the present invention. This is a characteristic infrared absorption spectrum of the 15 polymorphic Form V of sertraline hydrochloride of formula (I) in KBr.

The polymorphic Form V of sertraline hydrochloride of formula (I) characterised by the following data:

20 Sertraline hydrochloride Form - V is characterized by powder X-ray diffraction (XRPD) pattern as set out in Table 1 given below:

**Table 1**

Serial No.	Diffraction Angle $\pm 0.2^\circ$ (degree two theta)	Lattice Spacing (D) (Angstroms)
1	5.2	17.119
2	10.9	8.122
3	14.1	6.259

Serial No.	Diffraction Angle $\pm 0.2^\circ$ (degree two theta)	Lattice Spacing (D) (Angstroms)
4	16.3	5.433
5	17.1	5.181
6	19.0	4.671
7	19.7	4.506
8	20.9	4.256
9	22.0	4.046
10	23.0	3.860
11	23.5	3.776
12	25.3	3.517
13	25.9	3.437
14	29.0	3.075

The sertraline hydrochloride that results from practicing the invention as exemplified herein can be characterised by its powder X-ray diffraction pattern. Fig. 1 is a representative pattern of sertraline hydrochloride Form V. The principal peaks observed are at about  $5.2 \pm 0.2$ ,  $10.9 \pm 0.2$ ,  $14.1 \pm 0.2$ ,  $16.3 \pm 0.2$ ,  $17.1 \pm 0.2$ ,  $19.0 \pm 0.2$ ,  $19.7 \pm 0.2$ ,  $20.9 \pm 0.2$ ,  $22.0 \pm 0.2$ ,  $23.0 \pm 0.2$ ,  $23.5 \pm 0.2$ ,  $25.3 \pm 0.2$ ,  $25.9 \pm 0.2$  and  $29.0 \pm 0.2^\circ$  2 theta.

- 10 The IR spectrum of sertraline hydrochloride Form V produced by present process is characterized by the following bands:

15  $773\text{ cm}^{-1}$ ,  $1011\text{ cm}^{-1}$ ,  $1032\text{ cm}^{-1}$ ,  $1054\text{ cm}^{-1}$ ,  $1134\text{ cm}^{-1}$ ,  $1330\text{ cm}^{-1}$ ,  $1561\text{ cm}^{-1}$  and  $1591\text{ cm}^{-1}$  as shown in figure 2.

FT IR spectrum was recorded in solid state as KBr dispersion using Shimadzu FT IR 8700 series FT IR Spectrophotometer.

- 20 The pharmaceutical composition of sertraline hydrochloride Form V can be prepared by using the above referred chemical compound complying the following tests :

Sr. No.	Tests	Limits
1.	Related substances (%)(by HPLC) Total known and unknown impurities	Not more than 0.50
2.	Sulphated ash (%)	Not more than 0.2
3..	Heavy Metals (ppm)	Not more than 20
4.	Assay (%)(By titration)	98.0 to 102.0; on anhydrous basis
5.	Residual solvents (ppm) (a) Isopropyl alcohol (b) Methanol (c)Acetone (d)Methylene chloride	Not more than 2000 Not more than 100 Not more than 100 Not more than 200
6.	Polymorph by XRD	2 Theta Values(D) : 5.2(17.119), 10.9 (8.122), 14.1(6.259), 16.3 (5.433), 17.1(5.181), 19.0 (4.671), 19.7(4.506), 20.9 (4.256), 22.0 (4.046), 23.0 (3.860), 23.5 (3.776), 25.3 (3.517), 25.9 (3.437) and 29.0 (3.075)
7.	IR ( $\text{cm}^{-1}$ )	773, 1011, 1032, 1054, 1134, 1330, 1561 and 1591
8.	Particle size (By Sizer) Below 20 $\mu\text{m}$	Not less than 90.0 %
9.	Microbial limit tests Total aerobic count (cfu/g) Total fungal count (cfu/g) E.coli	Not more than 1000 Not more than 100 Should be absent

In the following section preferred embodiments are described by way of examples to illustrate the process of this invention. However, this is not intended in any way to limit the scope of the present invention.

## PREPARATORY EXAMPLES

### Preparation of sertraline mandelate from racemic HCl salt of sertraline.

5

In a one liter round bottom flask methylene chloride (250 ml), water (250 ml) and racemic HCl salt of sertraline (50 gm) at room temperature were taken. To it 20% sodium hydroxide solution (10 gm sodium hydroxide solution in 50 ml of water) was 10 added to adjust pH between 9 to 10 as detected on pH paper. Stirred for 45 minutes till clear solution was obtained. Methylene chloride layer was separated and aqueous layer extracted with methylene chloride twice (50 ml for each extraction). All methylene chloride layers combined and washed with water till the pH reaches at 7 to 8. All methylene chloride layers are collected and distilled out under vacuum at 15 60°C to get an oil. Methanol 200 ml is charged into it and then heated to 50-55°C. D(-) Mandelic Acid solution (23 gm in 50 ml methanol) added to it at 55-60°C. The temperature raised to 60-65°C and maintained for 10 minutes. The mass cooled to 30-35°C in 1 hr. and further chilled to 20-25°C and temperature maintain at that level for 30 minutes to get solid. The solid is filtered and washed with acetone 3 times (25 20 ml each) to get sertraline mandelate with dry weight: 28.0 gm.

### Preparation of sertraline hydrochloride Form V from sertraline mandelate

In 1 litre 4 neck round bottom flask equipped with stirrer, thermometer pocket and 25 water condenser, sertraline mandelate (25 gm) was added at room temperature. To it, 200 ml of isopropyl alcohol was added under stirring. The pH of the solution was adjusted to 1 to 2 by adding concentrated HCl. To it, 5 ml water was added and heated to reflux to get the clear solution. The solution was filtered through hyflow

bed and cooled it to room temperature to get 23 gm of the white solid which was dried further to get 13 gm of dried material of Form V.

### Pharmaceutical Compositions

5

The pharmaceutical compositions of sertraline hydrochloride Form V should preferably have a particle size below  $20\mu$  and purity not less than 90% when prepared in admixture with pharmaceutically acceptable diluent, carrier or excipient. The impurity level of sertraline hydrochloride in such composition should preferably not exceed 0.50% with sulphated ash content not more than 0.2% and heavy metals not more than 20 ppm preferably sertraline hydrochloride used for such composition has the assay figure by titration between 98.0 to 102% on anhydrous basis.

The residual solvents in such composition are preferably in the following limits :

15

(a) isopropyl alcohol	:	not more than 2000 ppm
(b) methanol	:	not more than 100 ppm
(c) acetone	:	not more than 100 ppm
(d) methylene chloride	:	not more than 200 ppm

20

The microbial limits in such composition are preferably as under :

total aerobic count (cfu/g)	:	not more than 1000
total fungal count (cfu/g)	:	not more than 100
E.Coli	:	should be absent.

25

While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.

30

## CLAIMS

1. A process for the production of sertraline salt comprising the steps of :
  - a) dissolving or suspending sertraline mandelate in a solvent ;
  - b) reducing the pH of the solution or the suspension, and
  - c) isolating salt of sertraline.
- 5  
2. A process for the production of sertraline hydrochloride Form - V comprising the steps of :
  - a) dissolving or suspending sertraline mandelate in a solvent ;
  - b) reducing the pH of the solution or the suspension, and
  - c) isolating sertraline hydrochloride Form V.
- 10  
3. The process as claimed in claim 1 or 2, wherein solvent used in step (a) is a protic solvent or a mixture of protic solvents selected from the group comprising of protic solvents or mixtures thereof.
- 15  
4. The process as claimed in claim 3, wherein protic solvent(s) used in step (a) is selected from the group comprising of alcohol, water or mixtures thereof.
- 20  
5. The process as claimed in claim 4, wherein said alcoholic solvent used in step (a) is selected from the group comprising of methanol, ethanol, n-propyl alcohol, isopropyl alcohol, n-butyl alcohol, t-butyl alcohol, isobutyl alcohol or mixtures thereof.

6. The process as claimed in claim 5, wherein said alcoholic solvent is isopropyl alcohol.

7. The process as claimed in claim 1 or 2 wherein said step(a) of dissolving or  
5 suspending is achieved by heating and / or stirring.

8. The process as claimed in claim 1 or 2, wherein said step (a) of dissolving or suspending sertraline mandelate in a solvent is carried out at temperature in the range of 20 to 90 °C.

10

9. The process as claimed in claim 8, wherein said range of temperature is 25 to 80°C.

10. The process as claimed in claim 9, wherein said range of temperature is 25 to  
15 30°C.

11. The process as claimed in claim 1 or 2, wherein an organic or inorganic acid is used for reduction of pH in step (b).

20 12. The process as claimed in Claim 11, wherein said acid used for reduction of pH is an inorganic acid.

13. The process as claimed in claim 12 wherein said acid is HCL.

14. The process as claimed in claim 13, wherein HCl is used in the form of a gas or dissolved in solvent.

15. The process as claimed in 14, wherein said solvent is water or organic solvent or  
5 mixtures thereof.

16. The process as claimed in claim 15, wherein said organic solvent is alcohol.

17. The process as claimed in claim 16, wherein said alcohol is selected from the  
10 group comprising of methanol, ethanol, n-propanol, isopropyl alcohol, n-butanol  
or mixtures thereof.

18. The process as claimed in claim 1 or 2, wherein pH is reduced to the range of 1 to  
3 in step (b).

15

19. The process as claimed in claim 18, wherein pH is reduced to the range of 1 to 2.

20. The process as claimed in claim 2, wherein isolation of sertraline hydrochloride  
Form V in step (c) is carried out by cooling the contents of step (b).

20

21. The process as claimed in claim 20, wherein the cooling is effected by allowing  
the solution to attain room temperature on its own or with mild coolants  
comprising of cold water, water, alcohol or mixtures thereof.

22. The process as claimed in claim 21, wherein said alcohol is selected from the group comprising of monohydroxy alcohols, dihydroxy alcohols or mixtures thereof.

5    23. Sertraline hydrochloride Form - V characterized by a powder X-ray diffraction pattern with peaks at about (2 Theta Values) :  $5.2 \pm 0.2$ ,  $10.9 \pm 0.2$ ,  $14.1 \pm 0.2$ ,  $16.3 \pm 0.2$ ,  $17.1 \pm 0.2$ ,  $19.0 \pm 0.2$ ,  $19.7 \pm 0.2$ ,  $20.9 \pm 0.2$ ,  $22.0 \pm 0.2$ ,  $23.0 \pm 0.2$ ,  $23.5 \pm 0.2$ ,  $25.3 \pm 0.2$ ,  $25.9 \pm 0.2$  and  $29.0 \pm 0.2$  degrees two-theta and an IR spectrum with peaks at about  $773 \text{ cm}^{-1}$ ,  $1011 \text{ cm}^{-1}$ ,  $1032 \text{ cm}^{-1}$ ,  $1054 \text{ cm}^{-1}$ ,  $1134 \text{ cm}^{-1}$ ,  $1330 \text{ cm}^{-1}$ ,  $1561 \text{ cm}^{-1}$  and  $1591 \text{ cm}^{-1}$ .

10

24. Sertraline hydrochloride Form - V characterized by powder X-ray diffraction (XRPD) pattern substantially as set out in the Table given below:

<b>Serial No.</b>	<b>Diffraction Angle <math>\pm 0.2^\circ</math> (degree two theta)</b>	<b>Lattice Spacing (D) (Angstroms)</b>
1	5.2	17.119
2	10.9	8.122
3	14.1	6.259
4	16.3	5.433
5	17.1	5.181
6	19.0	4.671
7	19.7	4.506
8	20.9	4.256
9	22.0	4.046

Serial No.	Diffraction Angle $\pm 0.2^\circ$ (degree two theta)	Lattice Spacing (D) (Angstroms)
10	23.0	3.860
11	23.5	3.776
12	25.3	3.517
13	25.9	3.437
14	29.0	3.075

25. Sertraline hydrochloride Form V characterized by IR spectrum with peaks at about  $773\text{ cm}^{-1}$ ,  $1011\text{ cm}^{-1}$ ,  $1032\text{ cm}^{-1}$ ,  $1054\text{ cm}^{-1}$ ,  $1134\text{ cm}^{-1}$ ,  $1330\text{ cm}^{-1}$ ,  $1561\text{ cm}^{-1}$  and  $1591\text{ cm}^{-1}$ .

5

26. Sertraline hydrochloride Form - V as claimed in claim 25 further characterized by a powder X-ray diffraction pattern as substantially depicted in Fig 1 of the accompanying drawings.

10 27. Sertraline hydrochloride Form - V of Claim 25 or 26 further characterized by an IR spectrum as substantially depicted in Fig 2 of the accompanying drawings.

15 28. A process for preparation of a pharmaceutical composition of sertraline hydrochloride Form - V, comprising mixing sertraline hydrochloride Form-V, of particle size below  $20\mu$  is not less than 90 % with pharmaceutically acceptable diluent, carrier or excipient.

29. The process for preparation of a pharmaceutical composition as claimed in claim 28, wherein the impurity level in sertraline hydrochloride Form V used is not more than 0.50% comprising of both known and unknown impurities.

5 30. The process for preparation of a pharmaceutical composition as claimed in claim  
29, wherein the sulphated ash in sertraline hydrochloride Form V is not more than  
0.2%.

31. The process for preparation of a pharmaceutical composition as claimed in claim  
10 29, wherein the heavy metals in sertraline hydrochloride Form V used is not more  
than 20 ppm.

32. The process for preparation of a pharmaceutical composition as claimed in claim  
28, wherein the assay by titration of sertraline hydrochloride Form V is between  
15 98.0 to 102.0 % on anhydrous basis.

33. The process for preparation of a pharmaceutical composition of as claimed in claim 28, wherein the residual solvents in the active ingredient sertraline hydrochloride Form V are :

- 20 (e) isopropyl alcohol : not more than 2000 ppm  
(f) methanol : not more than 100 ppm  
(g) acetone : not more than 100 ppm  
(h) methylene chloride : not more than 200 ppm

34. The process for preparation of a pharmaceutical composition as claimed in claim 28, wherein the microbial limits in active ingredient sertraline hydrochloride Form V are :

5           total aerobic count (cfu/g)     :     not more than 1000  
              total fungal count (cfu/g)     :     not more than 100  
              E.Coli                            :     should be absent.

10          35. A process for the preparation of sertraline hydrochloride Form - V, substantially as herein described, particularly with reference to the foregoing examples.

1/2




Fig. 1

2/2




Fig. 2

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/IB 03/04998

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC 7 C07C211/42

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, BEILSTEIN Data, CHEM ABS Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 03 051818 A (NIDAM TAMAR ; SINGER CLAUDE (IL); TEVA PHARMA (IL); ARONHIME JUDITH (I) 26 June 2003 (2003-06-26) claims 1-8,37-43; examples 4,11,22 page 10, line 16 -page 14, line 1 page 18, line 22 - line 26 ----	1-27,35
X	DATABASE HCAPLUS ACS; 2000 retrieved from STN Database accession no. 132:93107 XP002272490 abstract & JP 2000 026378 A (SUMIKA FINE CHEMICALS CO.) 25 January 2000 (2000-01-25) ---- -/-	1



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

4 March 2004

Date of mailing of the International search report

23/03/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Krische, D

## INTERNATIONAL SEARCH REPORT

International	Application No
PCT/IB 03/04998	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 32551 A (NIDAM TAMAR ; SINGER CLAUDE (IL); TEVA PHARMA (IL); LIBERMAN ANITA (IL) 8 June 2000 (2000-06-08) cited in the application	23-27
Y	claims 1,12-24 page 6, line 1 -page 10, line 6 page 17, line 21 -page 18, line 14 -----	1-22, 28-35
Y	WO 98 13335 A (DSM NV ; BOONEN JOZEF JOHANNES CATHARIN (NL)) 2 April 1998 (1998-04-02) claims 1,3,6 page 2, line 28 -page 3, line 1 -----	1-22, 35
Y	WO 01 47498 A (PFIZER PRODUCTS INC.) 5 July 2001 (2001-07-05) abstract; examples 6A,B page 22, line 9 -page 25, line 16 -----	28-34

**INTERNATIONAL SEARCH REPORT**

 International application No  
 PCT/IB 03/04998

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03051818	A	26-06-2003	US 6500987 B1 WO 03051818 A1 US 2002183555 A1 US 2003055112 A1 US 6495721 B1 US 6600073 B1	31-12-2002 26-06-2003 05-12-2002 20-03-2003 17-12-2002 29-07-2003
JP 2000026378	A	25-01-2000	NONE	
WO 0032551	A	08-06-2000	AU 1633600 A EP 1133459 A1 JP 2002531427 T WO 0032551 A1 US 2003055112 A1 US 6500987 B1 US 2002183555 A1 US 6495721 B1	19-06-2000 19-09-2001 24-09-2002 08-06-2000 20-03-2003 31-12-2002 05-12-2002 17-12-2002
WO 9813335	A	02-04-1998	BE 1010647 A3 AT 222887 T AU 4225697 A CN 1237959 A ,B DE 69715053 D1 DE 69715053 T2 EP 1019363 A1 ES 2182115 T3 HU 9903988 A2 JP 2001500896 T KR 2000048558 A WO 9813335 A1 PL 332426 A1 TW 476744 B	03-11-1998 15-09-2002 17-04-1998 08-12-1999 02-10-2002 24-04-2003 19-07-2000 01-03-2003 28-03-2000 23-01-2001 25-07-2000 02-04-1998 13-09-1999 21-02-2002
WO 0147498	A	05-07-2001	AU 1724301 A BR 0016707 A CA 2395231 A1 EP 1239839 A2 WO 0147498 A2 JP 2003518487 T US 2001044474 A1	09-07-2001 03-09-2002 05-07-2001 18-09-2002 05-07-2001 10-06-2003 22-11-2001